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Abstract: The topic of 24-hour management of COPD is related to day-to-night symptoms
management, specific follow-up and patients’ adherence to therapy. COPD symptoms strongly
vary during day and night, beingworse in the night and earlymorning. This variability is not always
adequately considered in the trials. Night-time symptoms are predictive of higher mortality and
more frequent exacerbations; therefore, they should be a target of therapy. During night-time, in
COPD patients the supine position is responsible for a different thoracic physiology; moreover,
during some sleep phases the vagal stimulation determines increased bronchial secretions, increased
blood flow in the bronchial circulation (enhancing inflammation) and increased airway resistance
(broncho-motor tone).Moreover, in COPDpatients the circadian rhythmmay be impaired. The role
of pharmacotherapy in this regard is still poorly investigated. Symptoms can be grossly differen-
tiated according to the different phenotypes of the disease: wheezing recalls asthma, while dyspnea
is strongly related to emphysema (dynamic hyperinflation) or obstructive bronchiolitis (secretions).
Those symptomsmaybe different targets of therapy. In this regard,GOLDrecommendations for the
first time introduced the concept of phenotype distinction suggesting the use of inhaled corticoster-
oids (ICS) particularly when an asthmatic pattern or eosiophilic inflammations are present, and
hypothesized different approaches to target symptoms (ie, dyspnea) or exacerbations.
Pharmacotherapy should be evaluated and possibly directed on the basis of circadian variations,
for instance, supporting the use of twice-daily rapid-action bronchodilators and evening dose of
ICS. Recommendations on day and night symptomsmonitoring strategies and choice of the specific
drug according to patient’s profile are still not systematically investigated or established. This
review is the summary of an advisory board on the topic “24-hour control of COPD and role of
pharmacotherapy”, held by five pulmonologists, experts in respiratory pathophysiology, pharma-
cology and sleep medicine.
Keywords: COPD, symptoms, dyspnea, night, sleep, follow-up, adherence, circadian
LAMA, LABA, ICS
Introduction
Chronic obstructive pulmonary disease (COPD) is a major global health problem,
being the fourth cause of death worldwide.1 Among other conditions, it has been
associated with chronic airways and lung parenchyma inflammation. At present,
available therapies are not capable of reversing the progression or completely
suppressing the inflammation associated with COPD itself. Therefore, there is
a pressing need to find new pathophysiological bases for treatments, as expressed
in the most recent 2020 Global initiative for chronic Obstructive Lung Disease
(GOLD) recommendations.2 In particular, the pattern of symptoms and long-term
disease control are still unmet needs.
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The present review is taken from a meeting in which five
pulmonologists, expert in respiratory pathophysiology, phar-
macology and sleep medicine discussed the topic “24-hour
control of COPD and the role of pharmacotherapy” from
different points of view by means of lectures and plenary
debate. The areas covered by the discussion and presented in
this article refer to the stable patient and can be resumed in:
circadian variation of COPD symptoms and its pathophysiol-
ogy, disease management during follow-up, pharmacother-
apy and 24-hour symptoms control, patients’ adherence.
COPD Symptoms: Circadian
Variation and Prognostic Impact
COPD is characterized by a lot of symptoms including
dyspnea, cough, wheezing, fatigue and phlegm.3
Symptoms worsening is crucial since it precedes exacerba-
tions. To reduce symptoms is one of the immediate aims of
COPD therapy according to the GOLD document.2 They
suggest assessing the impact of COPD on a patient’s life by
means of the COPD Assessment Test (CAT) questionnaire,
which includes dyspnea as well as cough and phlegm.
However, apart from dyspnea, the other symptoms (eg,
wheezing, fatigue, phlegm, cough) are generally lacking
in studies and scores. New domains must be explored to
better characterize patients. Indeed, the symptom with the
worst impact on patients’ disability is dyspnea, principally
in those with moderate COPD.4 The variability of COPD
symptoms during day and night is well known. In
particular, they are worse during night and in the morning,
especially when COPD is severe (Figure 1).4 37% of all
COPD patients and 73% of those with severe disease
reported as troublesome the routine early morning
activities.5 The prevalence of night-time symptoms varies
according to GOLD classes, with the greater step up per-
centage between GOLD 2 and 3.6 Circadian variations are
more expressed at severe stages, showing a progressive
increase in the prevalence of both morning and night symp-
toms and depends on age, dyspnea severity, intensity of
therapy, physical activity. Moreover, night-time symptoms
are predictive of higher mortality and more frequent
exacerbations.6,7 They are also partly responsible for early
morning symptoms. On the other hand, morning symptoms
increased the odds of poor health status at follow-up.7 In
addition, early morning symptoms can also be linked to
a mechanical issue, since the patients start to move. Night-
time symptoms can be assessed by specific questionnaires,
but they should be answered early after the awakening,
otherwise they lose sensibility, particularly in the elderly.
Recently, the LEOSound system has been developed and
validated, in order to register nocturnal wheezing and
cough, which remain otherwise unnoticed in COPD
patients.8 It is a mobile system used for automated long-
term recording and objective analysis of respiratory sounds,
like cough and wheezing, composed by a trachea micro-
phone and two lungs microphones. An internal ambient
microphone helps distinguishing lung sounds from
Figure 1 Circadian variation of COPD symptoms: *p<0.001 versus “midday”, “afternoon”, “evening”, “night” and “difficult to say” groups; p=0.006 versus “no particular
time of day” (all COPD patients); †p<0.001 versus “midday”. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an
internet survey. Partridge MR, Karlsson N, Small IR, et al. Curr Med Res Opin. 2009;25:2043–2048. Informa UK Ltd, trading as Taylor & Francis Group, reprinted by
permission of the publisher (Taylor & Francis Ltd, http://www.tandfonline.com).4
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environment noise.9 The authors found that these symp-
toms were common, particularly in smokers.8 The same
device has recently revealed a high rate of nocturnal
cough epochs in GOLD 3 than 2 or 4 (probably because
stage 4 might be associated with emphysema). In patients
who smoke cough is generally productive, while in the
others it is more frequently “normal”.10 New tools are
now available to objectively assess nocturnal symptoms
(instead of questionnaires). They provide quality data, dif-
ferentiating cough from snoring. Daytime cough is rarely
referred by patients because it is considered normal, parti-
cularly in smokers. Symptoms can be prevalent in different
phenotypes of COPD: wheezing is related to asthma or to
a bronchospastic condition (for instance at a certain phases
of exacerbation), while dyspnea is particularly associated
with emphysema (dynamic hyperinflation) or obstructive
bronchiolitis (secretions). All these symptoms may be dif-
ferent target of therapy. However, nocturnal symptoms
related to COPD must be differentiated to those related to
obstructive sleep apnea (OSA) syndrome, which can over-
lap with COPD. Nevertheless, the quality of sleep is often
inadequate in COPD patients, irrespective of the presence
or absence of OSA. In addition, it strongly impacts on
quality of life. Daytime vitality is worse in patients suffer-
ing from both COPD and OSA.11
Discrepancy exists between what patients refer and what
the physician measures in COPD. 90% of patients with
moderate COPD refer symptoms, but only 20% receive
a diagnosis and 25% are treated. Vice versa, all severe
COPD patients are symptomatic, with 50% receiving
a diagnosis and 60–70% a treatment.12 Patients suffering
from COPD define dyspnea as inspiratory difficulty or unsa-
tisfied inspiration, because of reduced displacement ratio per
breath with higher mechanical load.13 Beyond dyspnea, other
COPD symptoms vary consistently during day and night and
in the seasons. In the early morning, they are worse due to
a reduced airway clearance after the night,14 particularly in
severe COPD (Figure 1).4 This aspect could be well targeted
by the twice-daily bronchodilators administration: the eve-
ning dose acting on night-time and early morning symptoms.
In general, COPD symptoms are strongly related to inactivity
and deconditioning.15 Deconditioning, on the other hand,
determines a reduced symptom perception representing
another element of variability.
COPD Pathophysiology in
Determining 24-Hour Symptom
Variability (Figure 2)
Mechanical Issues
At a mechanical level, COPD is characterized by airways
flow limitation and hyperinflation, which are major deter-
minants of clinical outcomes including nocturnal symp-
toms, impaired quality of life, exacerbations, reduced
physical activity, and, importantly, increased mortality.16
a) At rest, COPD patients with moderate disease experi-
ence an altered mechanical condition in terms of volumes
and respiratory rate, similarly to healthy controls during
exercise. b) During exercise, these items worsen and the
exercise itself is shorter. An impaired respiratory
mechanics is on the basis of these phenomena, particularly
Figure 2 COPD pathophysiology in determining nocturnal symptom variability.
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referring to reduced compliance, increased resistance and
PEEPi. c) Activity-related dyspnea is one of the most
distressing symptoms experienced by COPD patients,
widely and variably occurring across the spectrum of dis-
ease severity17 and particularly impactful in the early
morning as a consequence of nocturnal alterations of
respiratory mechanics. d) In addition, activities of daily
living are reduced according to the severity of the disease,
as well as breathing discomfort.18 e) During night-time,
the supine position is responsible for a different thoracic
physiology. In particular, the recumbent surface reduces its
ventilatory ability as well as the chest wall outward elastic
recoil, Secretions accumulate in the lower part of the
lungs, as blood itself does, enhancing the ventilation/per-
fusion mismatch.19,20
Considering that COPD is heterogeneous in the lung par-
enchyma, this issue is variable. In addition, the cephalad force
of abdomen and the reduced diaphragm excursion due to
hyperinflation contribute to the pathophysiologic alterations
related to the supine position in COPD patients.
Comparing COPD patients and healthy controls by means of
pressure-volumes curves, Pecchiari et al demonstrated that the
closing volume was different in the two groups and in 50% of
COPD patients it was present at rest, meaning a 24-hour unfavor-
able breathing.21 Moreover, the airway cycling opening and clos-
ing should causemechanical damage and stimulate non-traditional
inflammation.21 The acute positive effects of different classes of
bronchodilators (namely, tiotropium vs indacaterol) on small air-
ways (ie, closing volume) and ventilation inhomogeneity were
compared in patients with moderate-severe COPD, finding no
interclass difference.22 In addition, bronchodilation improved the
vital capacity and the closing volume, without critical closing
pressure modification. After bronchodilators, the number of
patients breathing over their closing volume increased.22 This
should reduce the risk of small-airway impairment and positively
affect gas exchange. Key elements in the pathogenesis of COPD
are peripheral airway inflammation and dysfunction. The
exhaled alveolar fraction of nitric oxide (CANO) indirectly
reflects lung peripheral inflammation, correlating with airway
resistances, RV/TLC (Motley index), transfer factor and
FEV1.23 CANO was significantly reduced at 60 and 180
minutes compared to baseline for both formoterol and salme-
terol, but higher with formoterol, exhibiting amore rapid onset
of action. Changes in CANO were correlated with changes in
vital capacity and RV/TLC, but not FEV1. The reduction of
CANO was associated with amelioration in functional para-
meters reflecting air trapping. Indeed, long-acting β2-agonists
(LABA) acutely improve lung ventilation inhomogeneity
(which is enhanced in COPD during sleep) and favor lung
volume recruitment.23 The dynamic lung hyperinflation has
anatomical consequences on the heart.24 In fact, COPD is
a comorbidity that increase mortality for heart failure with
both reduced and preserved ejection fraction.25 Lung hyperin-
flation, increasing intrathoracic pressure, impairs biventricular
diastolic function. Considering that coronary arteries are per-
fused in diastole, left ventricular diastolic dysfunction has
negative effects on heart tissue perfusion. Consequently, lung
deflation has acute and chronic effects on both left and right
heart geometry and performance, either studied by echocardio-
graphy or cardiac magnetic resonance imaging.26–28 This
aspect may contribute to daytime activity-related symptoms
(eg dyspnea). Moreover, lung congestion and/or pulmonary
hypertension related to left heart remodeling can also worsen
night-time air trapping in the supine position. The functional
characteristics of COPD have a distribution that diverge from
differentGOLD stage and between different classification over
time. Particularly, in amulticenter observational study has been
reported that the functional GOLD 2007 classification better
reflected the pathophysiological COPD abnormalities com-
pared to the GOLD ABCD criteria; the transition from
GOLD 2011 to GOLD 2017 led to a significant shift from
high risk (C andD) to low risk categories (A andB) and that the
ABCD criteria poorly reflected the clinical heterogeneity (the
presence of chronic bronchitis and/or emphysema) of COPD
patients. Moreover, the clinical phenotype assessment recog-
nizes that the most frequent phenotype was the emphysema,
followed by themixed phenotype and lastly chronic bronchitis.
Furthermore, the phenotype distribution in the GOLD 2017
classification was similar across the ABCD subgroups.29 We
can argue that all the mechanical issues worsen in parallel with
COPD itself.
Sleep and Circadian Rhythm Regulation
Sleep is not safe for COPD patients. In the rapid eye
movement (REM) sleep phase the diaphragm is the only
muscle able to move, so that it has to substitute the other
respiratory muscles.30 The flatter the diaphragm is (due to
the cephalad force of abdomen), the less it contracts,
determining hypoventilation events. Consequently, these
events are more frequent in the second part of the night,
when REM phases are prevalent.31,32 Delta waves phases
are at higher risk, when the vagal stimulation (by means of
the activation of the rostral portion of the nucleus ambig-
uous and the dorsal motor nucleus of the vagus) deter-
mines increased bronchial secretions, blood flow increase
in the bronchial circulation (enhancing inflammation) and
Braghiroli et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
International Journal of Chronic Obstructive Pulmonary Disease 2020:151272
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
31
.1
57
.1
13
.1
65
 o
n 
25
-A
ug
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
airway resistance (broncho-motor tone). This is why in the
asthmatic patient, bronchospasm improves when he is
awake.33 The circadian rhythm influences the vagal activ-
ity on broncho-motor tone.34 This is a possible explanation
about the worsening of COPD symptoms night-time and at
awakening. In COPD patients, the circadian rhythm may
be impaired. The output from the central circadian clock in
the cerebral suprachiasmatic nucleus is a source of timing
information to let peripheral clocks to identify day and
night, as they lack light input. The molecular circadian
clock consists of interlocking transcriptional and transla-
tional feedback loops, culminating in the rhythmic expres-
sion of core clock genes. Clara cells are the peripheral
clocks in the lungs.35 For instance, hematogenous inflam-
mation is increased during night. As a consequence, the
timing of administration of both inhaled and systemic
drugs is pivotal for an efficacious treatment. In asthma,
parenchymal and bronchial eosinophils have a circadian
rhythm, increasing during night.36 In COPD, the oxidative
stress of tobacco smoke enhances the activity of kinases
and reduces that of phosphatases, thus determining abnor-
mal clock protein rhythms. The role of pharmacotherapy
in this regard is unknown but inhaled corticosteroids
(ICS), for instance, could be useful during night.
Moreover, the role of bronchodilators on the circadian
alterations has not been studied yet: the twice a day admin-
istration may be useful to restore, locally, the circadian
rhythm. In this regard, a possible explanation of the FEV1
reduction without exacerbations in some patients switch-
ing from ICS/LABA to long-acting muscarinic agonists
(LAMA)/LABA can be linked to these considerations.
Different patterns of bronchodilator response in COPD
have been described independently from age, gender and
ICS use: flow response with increased expiratory flow
reserve in chronic bronchiolitis, volume response with
reduced hyperinflation in emphysema. Accordingly,
FEV1 is increased in both categories, while FEV1/VC
only in the first one.37–39 Moreover, small airways remo-
deling and narrowing is responsible for a low ventilatory/
perfusion ratio in chronic bronchiolitis, while capillary
network reduction, related to alveolar wall destruction,
determines a high ratio in pure emphysema.
How to Monitor Disease Control:
From Guidelines to Clinical Practice
There are 18 clinical practice guidelines onCOPDpublished or
updated after 2000: only 12 include a separate paragraph on
disease monitoring and 9, quality of life.40 In fact, the follow-
up of lung function parameters is the most frequently recom-
mended monitoring routine (89% of them, using FEV1 or
FEV1/FVC), even if lung function and symptoms do not
necessarily correlate. In general, symptoms monitoring, exer-
cise tolerance, comorbidity, and smoking habits are recom-
mended regularly. Usually, the monitoring strategy is set up
according to disease severity. 6 guidelines do not provide any
information, 3 suggest that frequency should be based on the
local health care system, 9 that visits should be calibrated on
the disease gravity and progression, and 8 provide suggestions
for frequency of monitoring visits that varies from monthly to
yearly. However, no guidelines recommended an evidence-
based monitoring strategy.40 No mention is usually present
on the monitoring of symptoms variability as mentioned
above, new domains must be explored to better characterize
patients. According to MacNee, assessing and treating of
chronic diseases should be based on: severity, activity and
impact. The severity of a chronic disease (including COPD)
is inversely related to the functional reserve left to the damaged
organ (regarding COPD it can bemeasured by FEV1, IC/TLC,
PaO2, 6MWD, comorbidities). The degree of activity reflects
the intensity of the causal biological mechanisms: in COPD, it
can be measured by smoking, FEV1 decline, exacerbations,
weight, and biomarkers. Notably, severity and activity do not
always run in parallel. Finally, the impact of a disease depends
on the patient’s perception of both the activity and severity of
the disease: it is what patients report, eventually measurable,
for example, with mMRC, daily activity, CATscore.41 Several
questionnaires have been elaborated in the recent years about
COPD control: Capacity of Daily Living during the Morning
(CDLM) by Partridge et al42 and CAT by Jones et al43 are
commonly used. CAT includes also symptoms and quality of
sleep. The CAT score is composed of 8 items, namely: cough,
phlegm, chest tightness, breathlessness, activities, confidence,
sleep and energy. Interestingly, symptoms other from dyspnea,
sleep quality and daytime activities are combined in a simple
qualitative instrument to globally assess the COPD patient and
also to monitor the disease activity over time.43 In a pooled
analysis of two 6-month Phase III studies about aclidinium
bromide authors analyzed the impact of this twice-daily drug
through the Evaluating Respiratory Symptoms in COPD
(E-RS(™): COPD) scale (formerly EXACT-RS).44 This tool
was developed to meet the need for a standardized respiratory
symptom diary: it is an 11-item score assessing both overall
daily respiratory COPD symptoms (RS-Total score) and spe-
cific respiratory symptoms by means of three subscales (RS-
Breathlessness, RS-Cough & Sputum and RS-Chest
Dovepress Braghiroli et al
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Symptoms).45 Interestingly, aclidinium, given its twice-daily
posology, improved the score and its domains irrespective of
the GOLD degree. Moreover, the E-RS scores were signifi-
cantly correlatedwith other clinical outcomes, including health
status, relief-medication use and alternate measures of symp-
tom severity.44 Recently, Soler-Cataluña et al created a new
tool to evaluate COPD control, namely the “modified” control
criteria (MCC). Control was defined as the presence of low
clinical impact and clinical stability. To assess clinical impact,
the following clinical parameters were evaluated: the degree of
dyspnea, the use of rescue medication, the physical activity,
and the sputum color. Stability was calculated by clinical
changes and exacerbations in the last 3 months. The authors
found that MCC is predictive of the combined event (emer-
gency visit, hospitalization, or death) and identifies patients
with a better quality of life.46 Consequently, the concept of
control and the new MCC could usefully help in treatment
optimization. The stability is a good parameter, meaning inhi-
bition of deterioration. However, the term “control” is too
much related to asthma, it would be better to use “wellness”.
Recently a questionnaire about the awareness of COPD, simi-
lar to the CAT score, has been developed. The authors found
that among patients, the awareness is suboptimal and it is
associated with care/cure satisfaction.47
Sleep quality is related to health status.48 From question-
naires about the quality of sleep in COPD patients, we have
learnt that nocturnal symptoms have a prognostic role. Omachi
et al demonstrated that the more disturbed is sleep and the
worse is COPD (but not FEV1), being longitudinally predic-
tive ofCOPDexacerbations, emergency health care utilization,
and mortality.49,50 Moreover, in patients with overlap syn-
drome (COPD+OSA) the increased severity of hyperinflation
correlates with worse sleep efficiency, independently from
apnea and night-time hypoxemia.51
A recent publication has also showed, in COPD patients,
a correlation between higher CASIS score and a greater small
airways impairment, evaluated by impulse oscillometry.52
CASIS score is a very practical, self-administered 7-item
scale assessing sleeping problems associated specifically with
COPD and asthma in the previous week. Five items refer to
disturbance falling asleep or staying awake during the day. The
other two items regard sleep quality. A first raw score is
calculated from the sum of the seven items, which is then
linearly transformed to a scale ranging from 0 to 100. The
higher the score and the greater is sleep deterioration in the
previous week. Internal consistency (Cronbach’s alpha 0.91),
test–retest reproducibility (intraclass coefficient 0.84), and
concurrent validity (correlated with the St George’s
Respiratory Questionnaire, r=0.68) were good. In COPD,
CASIS score correlates with SGRQ.53
Patients and physicians have different hopes regarding
COPD therapy. Patients think about symptoms reduction,
increased exercise capacity, reduced use of emergency
drugs, reduced exacerbations, and improved quality of
life. Physicians, instead, aim at increased respiratory func-
tion, reduction of functional decline, and few adverse
events. The last scope of COPD therapy is the reduction
of mortality and the increased life expectancy, as reached
by smoke cessation, oxygen therapy and CPAP in those
with overlap syndrome. No drug was definitely demon-
strated to have this ability, although in the TORCH study
an ICS-LABA combination was able to promisingly
reduce the risk of death of 17.5%.54 In addition to the
prescribed therapy, accurate follow-up and adequate dis-
ease monitoring are also important to COPD control.
Notably, as reported above, monitoring some parameters
can be seen as a tool to verify the therapy efficacy.
However, apart from FEV1, tools evaluating how ventila-
tion changes over time are lacking so far. Only nocturnal
cardio-respiratory monitoring gives simple information
about dynamic hyperinflation, hypoventilation and hypox-
emia: these devices are dynamic and sensitive. The
LEOSound (Löwenstein Medical GmbH & Co. KG, Bad
Ems, Germany) cited above automatically records respira-
tory sounds.9 However, to date, cardio-respiratory moni-
toring systems are the most reliable but they have been
employed with aims different than pharmacological ther-
apy efficacy monitoring. The ongoing “STudio
Osservazionale sulla caratteRizzazione dei sIntomi delle
24 ore nei pazienti con BPCO” (STORICO) trial aims at
providing effective and patient-oriented care, evaluating
patients on the basis of lung function, frequency of symp-
toms (including sleep) and patient-perceived impact of
symptoms on their lives. On this basis, treatment decisions
are made case-by-case.55 Another ongoing study is
“choose your outcome”, which considers only outcome
related to exercise/movement.47
New tools, non-invasively monitoring respiratory rate
and ventilation, are incoming. They could be useful to better
characterize patients and to easily study drug response. In
the most commonly used questionnaires, the identification of
the key symptomatology for each patient is lacking: symp-
toms and their daily variability, retain their loyalty and
indicate the effects before and after therapy.
For completeness, in Table 1 are reported, the main
instruments found by the authors that consider, at least
Braghiroli et al Dovepress
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partially, symptoms in different moments of the day or
over the time. Their diffusion and their appropriate valida-
tion to assess therapy-response in COPD is highly
variable.
Tailored Therapy: Pharmacologic
Characteristics Related to the Day
and Night Therapeutic Effect
From Pathophysiology to Clinical Impact
Regarding tailored therapy and symptoms variability, noc-
turnal symptoms and small airways involvement are very
important. Bronchiolitis and emphysema are also relevant
pathological conditions. 62.7% of symptomatic patients
reported daily and/or weekly symptom variability. Patient-
perceived COPD symptoms vary daily and weekly, with
variable impact on everyday activities; morning being the
worst time of the day.14 The SARA study analyzed differ-
ent patterns of sleep disturbances in the geriatric popula-
tion with COPD or asthma: morning tiredness and early
awakenings were more prevalent.56 Omachi et al demon-
strated that the more disturbed is sleep and the worse is
COPD (but not FEV1), being longitudinally predictive of
COPD exacerbations, emergency health care utilization,
and mortality.49 Indeed, the more severe is COPD and
the more variable are symptoms during night and day. As
already mentioned, by means of the COPD and Asthma
Sleep Impact Scale (CASIS) score Basile et al found that
nocturnal symptoms in COPD are associated with periph-
eral airways alterations and with air trappers vs non-
trappers, but independent of the severity of FEV1.52
A sub-analysis of the STORICO study revealed that the
circadian rhythm of respiratory symptoms varies according
to clinical phenotypes: bronchiolitis is characterized by
higher circadian variability and more evident nocturnal
symptoms.52 Probably, small airways can be involved by
the increased cholinergic tone and the supine position
during night. This could lead to a different therapeutic
approach preference.
Pharmacology of LAMAs and LABAs:
Rationale for Combination Therapy
Data about pharmacology and its implication regarding the
clinical issues cited above are sparse. GOLDdocument recom-
mends classes of drugs (eg, LABA, LAMA, ICS, etc.) and not
molecules, according to the demonstrated effects on twomajor
outcomes.2 The aim of the therapy is to reduce symptoms and
risks (ie, disease progression, exacerbations, mortality).
Bronchodilators (namely, LABA, LAMA, theophylline or
their combinations) are pivotal to control symptoms. In mod-
erate-to-severe COPD, associating an ICS can further increase
the efficacy of bronchodilators, especially considering exacer-
bations. New molecules of these classes have been developed
in the recent years. Airways innervation is fundamental to
understand the mechanism of action of bronchodilators. The
vagus nerves are tonically active, in particular at night and
produce a stable, promptly reversible basal tone of the airway
smooth muscle, the so-called bronchomotor tone.57 LAMAs
block M1 and M3 receptors preventing their binding to acet-
ylcholine and airway smooth muscle contraction. Vice versa,
the stimulation of β2-adrenergic receptors activates adenylyl
cyclase and increases intracellular cAMP, relaxing airway
smooth muscle.58 These two systems are widely linked both
at pre-synaptic and post-synaptic levels,59 thus justifying the
combination of the two classes. The combination of LAMA/
LABA can be clinically relevant to improve air trappingwhich
has been already described as cause of symptoms variability in
the previous chapters. The first study to analyze the interaction
between LAMA and LABA is that of Cazzola et al, who
demonstrated that the combined inhalation of indacaterol and
Table 1 Tools to Assess COPD Symptoms Referring to Daily
Variability
Questionnaires or Patient
Reported Outcomes
Instrumental Tools
CAT43 Plethysmography (FEV1, FEV1/
FVC, IC/TLC, FRC, RV)
CDLM42 6MWT
mMRC Pulse oximetry
E-RS44,45 Cardio-respiratory tools
(LEOSound)
MCC46 Polysomnography
CASIS53
JSEQ
GCSQ42
NiSCI
EMSCI
MEMSI
Night-time, morning and daytime
COPD symptoms
Abbreviations: CASIS, COPD and Asthma Sleep Impact Scale; CAT, COPD
Assessment Test; CDLM, capacity of daily living during the morning; EMSCI, early
morning symptoms of COPD instrument; GCSQ, Global Chest Symptoms
Questionnaire; JSEQ, Jenkins Sleep Evaluation Questionnaire; mMRC, modified
Medical Research Council; E-RS, Evaluating respiratory symptoms; MCC, modified
control criteria; MEMSI, Manchester Early Morning Symptoms Index; NiSCI, Night-
time Symptoms of COPD Instrument; 6MWT, 6-minute walking test.
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glycopyrronium significantly anticipated at 15 minutes the
mean peak of bronchodilatory effect post-administration,
than the two molecules alone, afterwards there is maximal
efficacy.60 However, the various available associations differ
in terms of pharmacodynamic and thus administration.
Notably, in COPD patients, the presence of small-airway dys-
function increases in parallel with GOLD classifications and it
is closely related to a higher impact of the disease on health
status.61 β2-adrenergic receptors are more expressed in periph-
eral airways, while muscarinic ones at proximal levels.
However, muscarinic receptors are also expressed in periphery
on nonstructural cells (lymphocytes, dendritic cells, endothe-
lial cells) and activated by the so-called “non-neuronal” acet-
ylcholine in autocrine way released by epithelial cell in
response to inflammatory stimuli. This “non-neuronal” acet-
ylcholine has inflammatory properties on neutrophils, lympho-
cytes, macrophages and fibroblasts.62 Consequently, some
authors have discussed a possible role of LAMA inmodulating
inflammation. Profita et al demonstrated that LABA and
LAMA (namely, olodaterol and tiotropium) control the
bronchoconstriction and TGF-β1-mediated neutrophilic
inflammation in COPD in induced sputum supernatants.63
While co-administration of glycopyrronium/indacaterol
induces bronchodilation with synergistic improvement as evi-
denced by the increase in cAMP concentrations both airways
smooth muscle and bronchial epithelium associated with
a decreased release of acetylcholine from the epithelium; espe-
cially when these drugs are administered at low
concentrations.64
The effectiveness of theophylline has long been thought to
be due primarily to bronchodilatation, although it is now
known that these drugs also exhibit anti-inflammatory actions.
The predominant mechanism of action of theophylline has
traditionally been ascribed to non-selective inhibition of phos-
phodiesterase enzymes (PDE), but there is increasing evidence
that some of the clinical effects of theophyllinemight be due to
their mechanisms of action such as increasing histone deace-
tylase enzyme(s) activity (HDAC), or interference with certain
intracellular kinases. Theophylline has the distinct advantage
of being able to be administered orally and is still used in the
management of patients with obstructive pulmonary disease
steroid resistant, as a matter of act it has been demonstrated
additional benefit from combined theophylline and glucocorti-
costeroid therapy rather than increasing the dose of
glucocorticosteroids.65–69
The rapid onset of action of bronchodilators can be
a critical aspect to consider when choosing a therapeutic
option. Different drugs in the same class have variable
pharmacological properties. Considering treatment with
LABA or LAMA, the fastest products in terms of onset
of action, are represented, respectively, by formoterol70
and glycopirronium.71,72 On the other side, those two
active principles present a pharmacokinetic profile making
them suitable for a twice-daily administration. Both these
two features (ie, fast action and twice-daily administration)
may represent a reason of choice in patients requiring
rapid symptoms relief in the morning and in the evening.
Role of ICS in Dual and Triple Therapy:
Pharmacology and Outcomes
2020 GOLD recommendations suggest a management
algorithm for COPD patients, characterized by “review
(symptoms)”, “assess (adherence)” and “adjust (therapy/
device)”.2 Practically, they suggest an initial therapy based
on GOLD classes and a subsequent re-evaluation accord-
ing to dyspnea and exacerbations. Interestingly, for the
first time they introduce the concept of phenotype distinc-
tion, giving a very important role to ICS in case of ele-
vated blood eosinophils.2 Indeed, Pascoe et al recently
found that blood eosinophil count is a promising biomar-
ker of response to ICS in patients with COPD. It may be
used to stratify patients for different strategies to reduce
exacerbation rate.73 Regarding phenotyping, night-time
symptoms and their variability should as well represent
relevant aspect to guide a tailored therapy, even if they are
not considered in GOLD document. ICS drugs are mainly
discussed in the contest of a specific outcomes control:
COPD exacerbations. As discussed further in this article,
studies regarding fixed triple therapies have confirmed the
role of ICS in exacerbations prevention compared to
bronchodilators alone.74,75 The WISDOM trial found that
descaling from LABA/LAMA/ICS to LAMA/LABA in
complex patients with severe COPD did not increase
exacerbations but worsened dyspnea and reduced
FEV1.76 Supporting these results, Calzetta et al performed
a meta-analysis which revealed that ICS withdrawal did
not significantly increase the overall rate of COPD exacer-
bation, but impaired both lung function and quality of life,
albeit in a non-clinically relevant way. A strong clinical
need in understanding what is the real impact of ICS
withdrawal in COPD persists.77 Importantly, the correla-
tion between FEV1 and symptoms is weak, and FEV1
gives only a partial patient’s description. It could be useful
to differentiate patients whose FEV1 remains stable vs
those whose FEV1 declines in order to understand which
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subgroup benefits from LAMA/LABA and which from
LAMA/LABA/ICS to control this important aspect of
COPD prognosis. According to Reilly, ICS continuation
in patients assuming bronchodilators should be guided on
symptoms rather than on exacerbations.78 Indeed, the
SUNSET study about de-escalation of ICS to indacaterol/
glycopirronium in non-frequently exacerbating patients
with moderate-severe COPD confirmed a small, statisti-
cally relevant reduction in lung function, without differ-
ence in exacerbations. However, the higher exacerbation
risk found in the same study, in patients with ≥300 blood
eosinophils/μL withdrawing from ICS, suggests to apply
a careful follow-up and to avoid triple therapy
discontinuation.79 In addition, three different meta-
analyses suggested a role of ICS/LABA in reducing mor-
tality, without definitive conclusions.80–82 Manoharan et al
analyzed 4133 COPD patients and found that in those
exposed to ICS, co-use of LAMA (dual therapy) or in
combination with LABA (triple therapy) were associated
with reduced all-cause mortality, while concomitant use of
LABA without LAMA provided no reduction. In addition,
triple therapy alone conferred benefits on cardiovascular
mortality.83 Recent data on two fixed-triple therapies con-
firmed a positive effect on mortality75,84 and on the delay
of clinical important deterioration.85 The improvement in
outcomes can be related to inflammation reduction as
suggested by a recent meta-analysis:86 this can be
a therapeutic target. Long-term ICS treatment partially
influences the composition of extracellular matrix in mod-
erate-to-severe COPD. This is linked to increased lung
function, suggesting that long-term ICS modulates airway
remodeling thereby potentially preventing airway collapse
in COPD.87 These data agree with Tantucci et al, who
demonstrated that the loss of lung function, assessed as
FEV1 reduction, seems more rapid and so more important
in the initial phases of COPD. Consequently, to have an
impact on the natural history of COPD, it is logical to look
at the effects of treatment in the earlier stages.88 Finally,
considering the combination of three active principles, the
TRIBUTE trial compared beclometasone/formoterol/gly-
copirronium with indacaterol/glycopirronium in severe
and very severe symptomatic COPD with exacerbation
history, finding that triple therapy significantly reduced
the rate of moderate-to-severe exacerbations, without
increasing the risk of pneumonia, and improved FEV1
and quality of life.74 These results do not directly refer
to mild COPD, nevertheless a sub-analysis of the study
confirmed the same effect of the beclometasone/
formoterol/glycopirronium extrafine fixed triple combina-
tion in preventing exacerbations and improving both lung
function and quality of life, in patients with a lower risk of
exacerbations, without increasing the risk of pneumonia.89
Positive results in mild patients treated with a fixed-triple
combination were also confirmed by the KRONOS
study.90 The characteristics of the reported trials are sum-
marized in Table 2.
GOLD recommendations, therefore, currently suggest the
use of triple therapy for the follow-up of the patient, indepen-
dently of the severity of the disease, but mainly based on
exacerbation recurrence despite maintenance treatment, with
an increasing effect from the blood eosinophils count cut-off of
100/µL.2 A meta-analysis, undertaken to compare triple ther-
apy vsLABA/LAMAor single bronchodilators, suggested that
patients on single long-acting LABA or LAMA therapy or
LABA/LAMA combination, who still have exacerbations and
have blood eosinophil count ≥300/µL, could benefit from ICS/
LABA/LAMA combination: the combination of efficacy and
security favors LABA/LAMA, but efficacy favors triple ther-
apy. Moreover, for triple therapy, the number needed to harm
regarding pneumonia was 195, and it decreased to 34 (ie, an
increased risk of pneumonia) when considering only the stu-
dies that included fluticasone in the triple combination.91
Notably, ICS are not similar, nor the patients. Considering
administration, all ICS are effective with once-daily dosing,
but they are more effective when dosed twice daily.92
Fluticasone furoate, randomly tested in 5 different regimens
for asthma vs placebo, was similarly effective (non-inferiority)
on 8-week pre-dose FEV1 either when administered twice
daily or once daily in the evening.93 The same non-inferiority
was found for a halved dose and at a 4-week follow-up.94
Twice Daily or Once Daily Administration
As reported above, dyspnea and other COPD symptoms
vary consistently during day and night and over seasons.
In the early morning, they are worse due to a reduced
airway clearance after the night and the clinostatic
position,14 particularly in severe COPD.5 This issue may
support the twice-daily bronchodilators administration: the
evening dose can act on night-time and early morning
symptoms.
Use of reliever medication, in COPD, is not consid-
ered a strong indicator of disease control, as it is in
asthma. Speculatively, the normally repeated dose of
a twice-daily fast-acting maintenance drug could poten-
tially work at the same time as potential reliever, possi-
bly reducing the need of rescue medications. In asthma,
Dovepress Braghiroli et al
International Journal of Chronic Obstructive Pulmonary Disease 2020:15 submit your manuscript | www.dovepress.com
DovePress
1277
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
31
.1
57
.1
13
.1
65
 o
n 
25
-A
ug
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
the last GINA document has clearly identified the role
of ICS-formoterol as the preferred reliever therapy (off-
label at the time the document was released), and sup-
ports the use of the maintenance and reliever therapy.95
This is mainly to reduce possible disease exacerbations.
In COPD this concept maybe quite undue, but can be
intriguing, suggesting to better consider the effect of the
drugs on the use of rescue medications.
Table 2 Charactestistics of the Main Trial Reported by the Board
Trial Drugs Population Primary
Outcome
Results Outcomes
Related to
Symptoms
Control
WISDOM76 Tiotropium (18 μg once daily),
salmeterol (50 μg twice-daily),
and fluticasone propionate
(500 μg twice-daily) vs
tiotropium-salmeterol
2485 patients with
a history of exacerbation
of COPD
Time to the first
moderate or
severe COPD
exacerbation;
change in trough
FEV1
Noninferiority; reduction in
FEV1 in the second group
SGRQ,
mMRC
SUNSET79 Indacaterol/glycopyrronium
(110/50 μg once-daily) vs
tiotropium [18 μg] once-daily
+ salmeterol/fluticasone
propionate [50/500 μg] twice-
daily)
1053 nonfrequently
exacerbating patients
with moderate-to-severe
COPD
Change from
baseline in trough
FEV1; moderate
or severe
exacerbations
Reduced FEV1 in the first
group; no difference in
exacerbations
TDI, SGRQ,
mean rescue
medication
use
TRIBUTE74 Two inhalations of extrafine
beclometasone dipropionate,
formoterol fumarate, and
glycopyrronium (87 μg/5 μg/9
μg) twice-daily or one
inhalation of indacaterol plus
glycopyrronium (85 μg/43 μg)
once-daily
1532 patients with
severe or very severe
COPD and at least one
moderate or severe
exacerbation in the
previous year
Rate of
moderate-to-
severe COPD
exacerbations
across 52 weeks
of treatment
Rate ratio of 0.848
(0.723–0.995, p=0.043) in
favour f beclometasone
dipropionate, formoterol
fumarate, and glycopyrronium
SGRQ,
SGRQ
response
(decrease
from
baseline in
total score
≥4), rescue
medication
use, E-RS,
CAT
IMPACT75 Once-daily combination of
fluticasone furoate (100 μg),
umeclidinium (62.5 μg) and
vilanterol (25 μg) vs fluticasone
furoate (100 μg) and vilanterol
(25 μg), vs umeclidinium (62.5
μg) and vilanterol (25 μg)
10,355 COPD patients Annual rate of
moderate or
severe COPD
exacerbations
Fewer exacerbations in the
triple therapy group than
fluticasone furoate-vilanterol
(rate ratio 0.85; 0.80–0.90;
P<0.001) and than
umeclidinium-vilanterol (rate
ratio 0.75; 0.70–0.81; P<0.001)
SGRQ,
health-
related
quality of life,
BDI, TDI
KRONOS90 Budesonide/glycopyrrolate/
formoterol fumarate metered-
dose inhaler (320 μg/18 μg/9.6
μg) vs glycopyrrolate/
formoterol fumarate metered-
dose inhaler (18 μg/9.6 μg) vs
budesonide/formoterol
fumarate metered-dose
inhaler (320 μg/9.6 μg) vs
open-label budesonide/
formoterol fumarate dry-
powder inhaler (400 μg/12 μg)
1902 COPD patients FEV1 area under
the
curve from 0–4
h over 24 weeks,
change from
baseline in
morning pre-dose
trough FEV1
Improvement in FEV1 and in
pre-dose trough FEV1 with
the triple therapy
TDI focal
score,
change from
baseline in
daily rescue
medication
use, change
from
baseline in
SGRQ total
score, E-RS
Abbreviations: BDI, Baseline Dyspnea Index; CAT, COPD Assessment Test; mMRC, modified Medical Research Council; SGRQ, St. George’s Respiratory Questionnaire;
TDI, Transition Dyspnea Index.
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Another mechanical reason supporting the twice-daily
administration of bronchodilators is given by the presence
of closing volume at rest in at least 50% of COPD
patients:21 in clinostatism, the cephalad force of abdomen,
and the enhanced ventilation/perfusion mismatch during
sleep may aggravate this phenomenon, so that the evening
administration of a rapid-action, long-acting bronchodila-
tor may be beneficial during night and have positive con-
sequences on the early morning symptoms.22 Moreover,
the small airways can be involved by the increased choli-
nergic tone and the supine position during night: rapid-
action bronchodilators administered in the evening can
reduce air trapping and cholinergic tone before sleeping,
with the same positive consequences.
In COPD patients, the circadian rhythm influencing the
broncho-motor tone may be impaired34 while Clara cells
act as peripheral clocks in the lungs.35 Considering that
hematogenous inflammation is increased during night as
well as parenchymal and bronchial eosinophils in the
asthmatic patient,36 the timing of administration of drugs
may be pivotal. There are no specific evidences in this
regard but, for instance, ICS administration could be use-
ful during night. Moreover, the role of bronchodilators on
the circadian alterations has not been studied yet: the twice
daily administration may be useful to restore the circadian
rhythm.
A study considering bid vs qd administration is that of
Beier et al, who compared aclidinium twice-daily and
tiotropium once-daily. In the study, aclidinium provided
additional improvements in bronchodilation, particularly
during the night-time, early-morning and night-time symp-
toms, early-morning limitation of activity.96 In a meta-
analysis, tiotropium administration in the evening vs in
the morning did not differ according to night-time
awakenings.97 This meta-analysis has several limitations,
including the self-reported outcomes by patients and the
inclusion of studies started in 1997. Moreover, the main
issue is not related to the best moment of administration of
a 24h lasting drug, but to the preference of a twice daily
posology. Moving on to pure pharmacology, the choice of
the available different formulations of active principles
should also consider the best profile of the drug. For
instance, glycopirronium shows a profile more suitable
for a twice-daily administration in order to guarantee
a best coverage in terms of bronchodilation over the 24
hours.98 Notably, apart from the US market where glyco-
pirronium is available as single agent to be administered
twice daily, in Europe it is available in this posology, only
in the triple combination beclometasone/formoterol/glyco-
pyrronium. Some data demonstrated that Tiotropium pro-
duced sustained bronchodilation throughout the 24 hour
day without necessarily abolishing circadian variation in
airway calibre. Particularly, this findings show that tiotro-
pium once daily, whether administered in the morning or
evening, results in sustained improvements in spirometric
indices throughout the 24 hours, including improvement in
the early morning nadir in spirometric values, without
necessarily affecting circadian variability;99 this could be
probably due to its prolonged pharmacologic effect.
Despite all, posology itself is seldom considered in the
experiences available in the literature, and consequently in
the different guidelines. Even if posology does not seem to
directly affect the efficacy of the drug on the commonest
considered outcomes, the type of patient’s symptomatol-
ogy and variability has never been used as inclusion or
selection criteria of clinical trials. Therefore, the potential
of a double administration should not be neglected when
considering patient’s needs or disease variability. If we
consider the actual situation, in a recent observational
study, the inhaled therapy distribution has been evaluated
across GOLD stages showing a 43.6% of the entire study
population being treated with LABA/ICS/LAMA, 21.4%
with LABA/LAMA, 12.1% with LABA/ICS, 18.6 and
4.3% with LABA or LAMA alone, respectively. The
patients with reported frequent exacerbations were more
frequently on triple therapy (P=0.003); while the LAMA
monotherapy was the most frequently administered regi-
men in the patients with mild disease, whereas for those
ranked GOLD stage ≥ 2, the most frequently prescribed
regimen was triple combination therapy.29
Compliance, Administration
Modalities and Particles Dimension
Many respiratory diseases are chronic and so strongly
linked to patient–doctor relationship, disease perception
and adherence to therapy. 18% of patients spontaneously
discontinue the therapy, considering it too complex.100
A reduced adherence is related to increased hospitalization
and healthcare costs,101 as well as reduced 5-year
survival.102 In COPD patients, adherence ranges from
10% to 40%.103–109 Inhaler mishandling remains common
in real life and is associated with reduced disease control,
including emergency department visits and
hospitalizations.110 A meta-analysis of 62 trials demon-
strated that reduced out-of-pocket expenses, case
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management, and patient education with behavioral sup-
port all improved medication adherence.111 In COPD
adherence to therapy is determined by several factors
related to patients (health beliefs, cognitive abilities, self-
efficacy, comorbidities, psychological profile, conscien-
tiousness), physicians (method of administration, dosing
regimen, polypharmacy, side effects), and society (patient–
prescriber relationship, social support, access to medica-
tion, device training, follow-up).106 Evidence is still lack-
ing regarding administration modalities in COPD.
In the same context, a small study suggested that switch-
ing from twice-daily to once-daily asthma treatments may
improve compliance,112 whereas a randomized trial of the
two administration modalities confirmed greater mean
adherence rates with a once-daily dose regimen, without
a significant difference in clinical outcomes.113 Indeed, this
kind of studies is often complicated by several factors,
including close patient monitoring, resulting in higher
adherence rates than clinical practice.102,114 In addition,
adherence in trials is generally tested for shorter periods
than real life. However, again in the asthma scenario, both
once-daily and twice-daily modalities show a continuous
and significant reduction in adherence after 3 months of
therapy.115 In COPD, a study aiming to assess the degree of
adherence for once-daily and twice-daily regimens for
LAMAs administration in an area with a centralized control
of prescriptions did not find that patients who used twice-
daily medication had a lower adherence.116 On the contrary,
few evidences support the idea that once-daily administra-
tion favors patients’ adherence, but with low quality of
data.117,118 In a certain sense, while once-daily posology is
preferred by patients with a higher probability to be not
adherent,112,113 twice-daily posology may be preferred by
patients who need reassurance about being well controlled.
Both strategies can be worth it to guarantee optimal man-
agement of the adherence.118
Regarding administration modalities and compliance it is
important also to choose the correct inhaler. Several inhalers
exist, of complex usage. In addition, COPD patient is com-
plex, due to comorbidities.119 Both the aspects can impact on
the wrong use of inhalers. Some comorbidities are equally
present from GOLD 1 to 4.120 Different devices (ie, pressur-
ized metered dose inhaler, dry powered inhaler or nebulizer)
have typical advantages and limitations, which should be
considered according to patient’s characteristics.121,122
Handling errors increase with age and severity of
COPD.123 Coordination errors occur in 33% of patients,124
while 15–25% does not shake the pMDI inhaler correctly.125
In conclusion, inhalers are definitely equally efficacious if
properly used and chosen.126
According to GOLD recommendations, particles dimen-
sion influences the total respirable fraction, the dose delivery
and the target site reached.2 Small-particle aerosol formula-
tions better target the distal lung, enhancing the drug delivery
efficiency,127 thus they target specific disease or receptor loca-
tions, decreasing drug exposure and adverse effects. Therefore,
new extrafine formulations may provide important clinical
benefit as regards symptoms, exacerbations, quality of life,
prognosis.61,127–129 Individual patient’s compliance to the cho-
sen device could be, finally, strongly related to the maximiza-
tion of the disease control achievable with the combination of
the inhalation technique, the intrinsic characteristics of the
formulation (influencing drug delivery) and the active princi-
ples’ efficacy.
Future Directions and Conclusions
COPD is a severe disease, highly disabling and impacting
on quality of life and survival. Symptoms are heteroge-
neous partly along with phenotypes, namely emphysema,
obstructive bronchiolitis, overlap with asthma. Dyspnea is
the most referred symptom, but also others are present and
should be considered in disease assessment and monitor-
ing (eg, cough, wheezing, fatigue, phlegm). Notably, inde-
pendently from the GOLD class, these symptoms also vary
during night and day, generally being worse in night-time
and after the awakening, and impacting on the quality of
sleep and ultimately on exacerbations and survival. The
cyclic variation of COPD symptoms is related to mechan-
ical issues (clinostatism, reduced respiratory surface,
cephalad force of the abdomen, increase ventilatory/perfu-
sion ratio) acting on the closing volume at rest and on
small airways, favouring air trapping. Additionally, also
biochemical alterations on the circadian regulation due to
cholinergic system and Clara cells action on the broncho-
motor tone and to hematogenous inflammation (particu-
larly eosinophilic), have a role in the genesis of night-time
symptoms. Consequently, this board argues that pharma-
cotherapy should be studied and directed towards these
aspects, for instance supporting the use of twice-daily
rapid-action bronchodilators and evening dose of ICS.
The concept of a tailored therapy based on the patients’
needs, including the daily variability of symptoms, is
intriguing and requires dedicated studies. In addition, the
use in clinical practice or in research field of instruments
such as questionnaires, cardiorespiratory recording devices
or new digital tools is advocated for disease monitoring,
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providing also objective data to support the therapeutical
choice.
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